Whether adagrasib (Krazati) can be taken on an empty stomach and analysis of its relationship with eating

Adagrasiib (Krazati) is a drug that targets specific genetic mutations and is used to treat certain types of non-small cell lung cancer. For patients, the correct way of taking medication directly affects the absorption and efficacy of the drug, so it is important to know whether it can be taken on an empty stomach. According to clinical pharmacology studies, the absorption of adagrasib is affected by gastric contents, but the range of change is limited, which means that the drug can be taken on an empty stomach or after meals, but it needs to be maintained regularly to ensure stable blood concentration.

When adagrasib is taken on an empty stomach, the drug absorption rate may be slightly faster, and the time for the blood drug concentration to reach peak value is relatively shortened. However, for patients with a sensitive gastrointestinal tract, taking the drug on an empty stomach may increase the risk of nausea or stomach discomfort, so it is recommended to take it after a meal to reduce gastrointestinal adverse reactions. Clinically, doctors usually choose a regimen of taking it on an empty stomach or with food based on the patient's individual situation.

If taken with food, the overall bioavailability of adagrasib will not be significantly affected. Eating can buffer gastric irritation and help patients adhere to long-term medication. However, taking it with high-fat or greasy foods should be avoided, as such foods may delay drug absorption and slightly prolong the onset of action, but have little effect on the overall efficacy.

In short, adagrasiib can be taken on an empty stomach or after meals, but the time and method of taking the drug must be kept stable. Patients should strictly follow the doctor's instructions during use and choose the medication method based on their own gastrointestinal tolerance. At the same time, the efficacy and adverse reactions are regularly monitored, and the medication method is adjusted according to clinical feedback when necessary to ensure the safety of treatment and stable efficacy.

Reference materials:https://www.drugs.com/